Evidence map›Paper›PMID 22967398›Full record

ArticleArthritis research & therapy2012

Matrilin-3 induction of IL-1 receptor antagonist is required for up-regulating collagen II and aggrecan and down-regulating ADAMTS-5 gene expression.

Chathuraka T Jayasuriya, Mary B Goldring, Richard Terek, Qian Chen

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Suppressing Chondrocyte Hypertrophy to Build Better Cartilage.Bioengineering (Basel, Switzerland) · 2023
    Review
  7. Review
  8. Review
  9. Articular Cartilage Regeneration in Veterinary Medicine.Advances in experimental medicine and biology · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chathuraka T Jayasuriya
Mary B Goldring
Richard Terek
Qian Chen
Brown University · USCornell University · US

Funding

RI COBRE: REGULATION OF GROWTH PLATE DEVELOPMENT BYNUCLEAR/CYTOPLASMIC FACTORSP20RR024484 · NCRR · RHODE ISLAND HOSPITAL · PI TEREK, RICHARD M · 2007 to 2011
$11.9M
COBRE for Skeletal Health and RepairP20GM104937 · NIGMS · RHODE ISLAND HOSPITAL · PI CHEN, QIAN · 2012 to 2016
$10.8M
Role of ESE1 Regulation of Type II Collagen in CartilageR01AG022021 · NIA · HOSPITAL FOR SPECIAL SURGERY · PI GOLDRING, MARY B · 2002 to 2014
$3.4M
BIOPHYSICAL REGULATION OF CHONDROCYTE DIFFERENTIATIONR01AG017021 · NIA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI CHEN, QIAN · 1998 to 2010
$2.1M
Stabilization of Matrix Structure in Mature CartilageR01AG014399 · NIA · RHODE ISLAND HOSPITAL · PI CHEN, QIAN · 2004 to 2008
$1.7M
STABILIZATION OF MATRIX STRUCTURE IN MATURE CARTILAGER29AG014399 · NIA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI CHEN, QIAN · 1997 to 2001
$119k
NCRR NIH HHS RR024484NIA NIH HHS AG 014399NIA NIH HHS AG 017021NIA NIH HHS R01 AG022021NIA NIH HHS R01-AG022021NIGMS NIH HHS P20 GM104937
6 · The paper itself

Abstract

introductionDeletion or mutation of the gene encoding the cartilage extracellular matrix (ECM) protein matrilin-3 (MATN3) results in the early onset of osteoarthritis (OA), suggesting chondroprotective properties of MATN3. To understand the mechanisms underlying these properties, we determined the effects of MATN3 protein on the expression of several key anabolic and catabolic genes involved in chondrocyte homeostasis, and the dependence of such regulation on the anti-inflammatory cytokine: IL-1 receptor antagonist (IL-1Ra).

methodsThe effects of recombinant human (rh) MATN3 protein were examined in C28/I2 immortalized human chondrocytes, primary human chondrocytes (PHCs), and primary mouse chondrocytes (PMCs). Messenger RNA levels of IL-1Ra, COL2A1, ACAN, MMP-13, and ADAMTS-4 and -5 were determined using real-time RT-PCR. Knocking down IL-1Ra was achieved by siRNA gene silencing. IL-1Ra protein levels were quantified by ELISA and the Bio-Plex Suspension Array System. COL2A1 protein level was quantified using Western blot analysis. Statistic analysis was done using the two-tailed t-test or one-way ANOVA.

resultsrhMATN3 protein induced gene expression of IL-1Ra in C28/I2 cells, PHCs, and PMCs in a dose- and time-dependent manner. Treatment of C28/I2 cells and PHCs with MATN3 protein stimulated gene expression of COL2A1 and ACAN. Conversely, mRNA levels of COL2A1 and ACAN were decreased in MATN3 KO mice. MATN3 protein treatment inhibited IL-1β-induced MMP-13, ADAMTS-4 and ADAMTS-5 in C28/I2 cells and PHCs. Knocking down IL-1Ra abolished the MATN3-mediated stimulation of COL2A1 and ACAN and inhibition of ADAMTS-5, but had no effect on MATN3 inhibition of MMP-13 mRNA.

conclusionOur findings point to a novel regulatory role of MATN3 in cartilage homeostasis due to its capacity to induce IL-1Ra, to upregulate gene expression of the major cartilage matrix components, and to downregulate the expression of OA-associated matrix-degrading proteinases in chondrocytes. The chondroprotective properties of endogenous MATN3 depend partly on its induction of IL-1Ra. Our findings raise a possibility to use rhMATN3 protein for anti-inflammatory and chondroprotective therapy.

Indexed as

ADAM ProteinsADAMTS5 ProteinAggrecansAnimalsCell LineCells, CulturedChondrocytesCollagen Type IIDose-Response Relationship, DrugDown-RegulationGene Expression RegulationHomeostasisHumansInterleukin 1 Receptor Antagonist ProteinMatrilin ProteinsMiceADAM ProteinsADAMTS5 ProteinADAMTS5 protein, humanAdamts5 protein, mouseAggrecansCollagen Type IIInterleukin 1 Receptor Antagonist ProteinMatrilin ProteinsRecombinant ProteinsRNA, Small Interfering

Identifiers

PMID22967398
PMCPMC3580507
OpenAlexW2152015295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.